JulieElizabeth(Holder)ChangMD

Hematology • Madison, WI

Physician

Join to view full profile

Dr. Chang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chang's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-263-7022

Fax+1 608-266-6020

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2005 - 2007
University of Wisconsin Hospitals and ClinicsFellowship, Medical Oncology, 2003 - 2005
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2000 - 2003
Indiana University School of MedicineClass of 2000

Certifications & Licensure

WI State Medical License 2001 - 2025
IL State Medical License 2007 - 2011
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Start of enrollment: 2009 Oct 01
Completed
Phase 2
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia Start of enrollment: 2011 Apr 27
Terminated
Phase 2
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Start of enrollment: 2013 Nov 12
Completed
Phase 2
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2013 Nov 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphom...
Julie E Chang, Danielle McQuinn, Meredith Hyun, KyungMann Kim, Vaishalee P Kenkre
Clinical Lymphoma, Myeloma & Leukemia. 2024-10-09
Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and ...
Julie E Chang, Tuo Wang, KyungMann Kim, Matthew Folstad, Mariah Endres
Leukemia & Lymphoma. 2024-10-01
21 citations
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis
Journal of the National Comprehensive Cancer Network. 2023-11-01

Abstracts/Posters

Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
Julie E Chang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

VcR-CVAD Yields High Responses, ‘Excellent’ Survival in MCLJanuary 11th, 2018
Will Maintenance Lenalidomide Become A Standard for Relapsed CLL?November 2nd, 2017
Wisconsin Cancer Patients Test Encouraging Lymphoma TreatmentDecember 23rd, 2016

Professional Memberships

American Society of Clinical Oncology - ASCO
Member